Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Waldenstrom Macroglobulinemia × ibrutinib × Clear all

Phase

Phase 2 12 Phase 1 9 Phase 3 4 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Graft vs Host Disease 1

Interventions

zanubrutinib 2 talquetamab 1 ibrutinib 1 Thiotepa 1 Thalidomide 1 Sirolimus 1 Rituximab 1 Radiotherapy 1 Prednisone 1 Filgrastim 1 Everolimus 1 Cyclophosphamide 1 Bortezomib 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡